Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $74.68M | $58.84M | +26.92% |
Cost of Revenue | $70.95M | $45.24M | +56.84% |
Operating Income | $-648.13M | $-479M | -35.31% |
Net Income | $-644.76M | $-463.66M | -39.06% |
EPS (Basic) | $-1.44 | $-1.69 | +14.79% |
EPS (Diluted) | $-1.44 | $-1.69 | +14.79% |
R&D Expense | $475.27M | $314.42M | +51.16% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $1.47B | $1.45B | +1.76% |
Current Assets | $812.85M | $714.27M | +13.80% |
Total Liabilities | $343.26M | $413.82M | -17.05% |
Current Liabilities | $147.71M | $187.47M | -21.21% |
Stockholders' Equity | $1.13B | $1.03B | +9.29% |
Cash & Equivalents | $743.29M | $594.35M | +25.06% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $-371.81M | $-359.17M | -3.52% |
Investing Cash Flow | $-16.87M | $260.06M | -106.49% |
Financing Cash Flow | $521.53M | $304.12M | +71.49% |
D&A | $83.7M | $36.49M | +129.36% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | -867.9% | -814.1% | -53.77% |
Net Margin | -863.4% | — | — |
ROE | -57.0% | — | — |
ROA | -43.7% | — | — |
Current Ratio | $5.503 | — | — |
Debt to Equity | $0.304 | — | — |
RXRX experienced significant revenue growth but faced increased costs and deepening net losses, highlighting operational challenges.
The company achieved a 26.9% increase in revenue, driven by expanded market reach and product offerings.
Source: Source: 10-K Income Statement, p.1
Cost of revenue surged by 56.8%, outpacing revenue growth and impacting margins negatively.
Source: Source: 10-K Income Statement, p.1
R&D expenses rose by 51.2%, reflecting the company's focus on innovation and long-term growth potential.
Source: Source: 10-K Income Statement, p.1
The company reported a significant operating loss of $648.1M, which could impact its ability to invest in growth and innovation.
Source: Source: 10-K Income Statement, p.1
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Biotechnology